Literature DB >> 7416187

Serum thyroglobulin levels predict total body iodine scan findings in patients with treated well-differentiated thyroid carcinoma.

M A Charles, L E Dodson, N Waldeck, F Hofeldt, N Ghaed, R Telepak, J Ownbey, P Burstein.   

Abstract

Forty-eight consecutive patients with treated thyroid carcinoma were studied with 131-I total body scans and serum thyroglobulin (hTg) levels. Serum hTg levels during thyroxine treatment accurately predicted scan results (chi square = 18.6, p < 0.001). All patients with negative scans (24 patients) had serum hTg levels (< 7 ng/ml whereas in patients with metastatic thyroid cancer (eight patients) they ranged from 11 to 690 ng/ml. In patients with iodine uptake confined to the thyroid bed (16 patients) serum hTg values ranged from 2 to 17 ng/ml. Serum hTg levels rose in patients with negative scans during hypothyroidism or after exogenous TSH suggesting that hTg levels are more sensitive than iodine scans in detecting residual thyroid tissue. Serum hTg levels could replace total body iodine scans in many patients with treated thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7416187     DOI: 10.1016/0002-9343(80)90011-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer.

Authors:  D Rubello; M E Girelli; D Casara; M Piccolo; A Perin; B Busnardo
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

2.  Misinterpretation of iodine uptake in papillary thyroid carcinoma and primary lung adenocarcinoma.

Authors:  W Langsteger; P Lind; P Költringer; A Beham; O Eber
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total body scan: results in 291 patients with thyroid cancer.

Authors:  M E Girelli; B Busnardo; R Amerio; D Casara; C Betterle; M Piccolo
Journal:  Eur J Nucl Med       Date:  1986

4.  The value of serum thyroglobulin measurement as a marker of cancer recurrence in the follow-up of patients previously treated for differentiated thyroid tumor.

Authors:  E Roti; G Robuschi; R Emanuele; P Bandini; A Russo; P Riva; E Galassi; U P Guerra; A Manfredi; A Bozzetti; A M Guazzi; A Gnudi
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

5.  Comparison of serum thyroglobulin with iodine scans in thyroid cancer.

Authors:  M A Charles
Journal:  J Endocrinol Invest       Date:  1982 Jul-Aug       Impact factor: 4.256

6.  Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up.

Authors:  Frank Berger; Ulla Friedrich; Peter Knesewitsch; Klaus Hahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-18       Impact factor: 9.236

7.  [Long-term observation of 15 patients with differentiated thyroid cancer and elevated plasma thyroglobulin levels of unclear origin].

Authors:  H P Stumpf; M Hüfner; H J Hermann; B Kimmig
Journal:  Klin Wochenschr       Date:  1984-05-02

8.  Immunoreactive thyroglobulin in sera and saliva of patients with various thyroid disorders: role of autoantibodies.

Authors:  A J Van Herle; P D Rosenblit; T L Van Herle; P Van Herle; M Greipel; K Kellett
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

9.  Scintigraphy with 201Tl for detection of thyroid cancer metastases.

Authors:  D A Piers; W J Sluiter; P H Willemse; H Doorenbos
Journal:  Eur J Nucl Med       Date:  1982

10.  Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy: study on 429 patients.

Authors:  M E Girelli; B Busnardo; R Amerio; G Scotton; D Casara; C Betterle; M Piccolo; M R Pelizzo
Journal:  Eur J Nucl Med       Date:  1985
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.